Welcome to our dedicated page for Golden Sun Technology Group Ltd. SEC filings (Ticker: GSUN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Golden Sun Technology Group Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Golden Sun Technology Group Ltd.'s regulatory disclosures and financial reporting.
Golden Sun Health Technology Group Limited is notifying investors about upcoming shareholder meetings and related proxy materials. The company will hold an extraordinary general meeting for holders of Class A ordinary shares on September 25, 2025, followed by its 2025 annual general meeting of shareholders on the same date.
The company is distributing a combined notice and proxy statement for Class A shareholders and a separate notice and proxy statement for Class B shareholders, both dated August 15, 2025. It is also providing proxy cards for Class A and Class B holders so they can vote on the matters to be presented at these meetings.
Golden Sun Health Technology Group Limited filed an amended Form 6-K to add details about an amendment to its existing financing. The company had previously issued a Senior Secured Convertible Note with an aggregate principal amount of $5,000,000 to two accredited investors under a Securities Purchase Agreement dated October 28, 2024, with closing on December 3, 2024. On August 15, 2025, the company and these investors signed Amendment No. 1 to the note, which removes the Adjusted Floor Price defined in the original note and any related adjustments. The amendment is attached as Exhibit 4.1 and this amended Form 6-K is also incorporated by reference into the company’s effective Form F-1 registration statement and related prospectuses.
Golden Sun Health Technology Group Limited furnished a Form 6-K that is incorporated by reference into its effective Form F-1 registration statement. The filing states that Unaudited Condensed Consolidated Financial Statements as of March 31, 2025 and for the six months ended March 31, 2025 and 2024 are attached as Exhibit 99.1, and that an Operating and Financial Review and Prospects for the same periods is attached as Exhibit 99.2.
The report contains a detailed cautionary statement about forward-looking statements and lists key risk assumptions including financial projections, growth and expansion execution, economic and political conditions, capital requirements, talent retention, competition in the education industry, and other assumptions. The document is signed on the company’s behalf by its Chief Executive Officer.